文献速递腹部MR

钆塞酸增强MRI衍生的功能性肝脏影像评分能否预测慢性肝病患者的结局

Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?
PubMed 文献 · Radiology · 2019-11-19

该研究纳入2011至2015年间接受钆塞酸增强肝脏MRI的265例慢性肝病患者,基于肝胆期肝实质强化、胆道排泄和门静脉信号强度三项特征计算功能性肝脏影像评分(FLIS)。在代偿期进展性慢性肝病患者中,FLIS可独立预测首次肝功能失代偿(校正HR 3.7)和死亡(校正HR 7.4);在失代偿期进展性慢性肝病患者中,FLIS可独立预测死亡(校正HR 3.8),但对进一步失代偿无独立预测价值。

要点

  • FLIS由肝胆期肝实质强化、胆道排泄和门静脉信号强度三项0-2分特征相加得出。
  • 代偿期进展性慢性肝病患者中,FLIS独立预测首次肝功能失代偿(校正HR 3.7)。
  • 代偿期和失代偿期进展性慢性肝病患者中,FLIS均独立预测死亡。

关键影像表现/征象

  • FLIS基于肝胆期三项特征评分之和:肝实质强化、胆道排泄和门静脉信号强度,每项按0-2分序数评分。
  • FLIS的观察者内信度κ=0.98(95%CI:0.97,0.99),观察者间信度κ=0.93(95%CI:0.90,0.95),均极好。

诊断标准与关键数值

  • FLIS为肝实质强化、胆道排泄和门静脉信号强度三项肝胆期特征评分(每项0-2分)之和。
  • 按纤维化分期及有无肝功能失代偿或病史,将患者分为非进展性慢性肝病、代偿期进展性慢性肝病和失代偿期进展性慢性肝病三组。

临床应用与阅片要点

  • 在代偿期进展性慢性肝病患者中,FLIS可独立预测首次肝功能失代偿(校正HR 3.7;95%CI:1.1,12.6;P=.04)。
  • 在失代偿期进展性慢性肝病患者中,FLIS对进一步肝功能失代偿无独立预测价值(校正HR 1.4;95%CI:0.9,1.9;P=.17)。
  • 在代偿期进展性慢性肝病患者中,FLIS为死亡的独立危险因素(校正HR 7.4;95%CI:2.7,20.2;P<.001)。
  • 在失代偿期进展性慢性肝病患者中,FLIS为死亡的独立危险因素(校正HR 3.8;95%CI:1.7,9.5;P=.004)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Gadoxetic acid-enhanced MRI enables estimation of liver function in patients with chronic liver disease (CLD). The functional liver imaging score (FLIS), derived from gadoxetic acid-enhanced MRI, has been shown to predict transplant-free survival in liver transplant patients. Purpose To investigate the accuracy of the FLIS for predicting hepatic decompensation and transplant-free survival in patients with CLD. Materials and Methods Patients with CLD who had undergone gadoxetic acid-enhanced liver MRI, including T1-weighted volume-interpolated breath-hold examination sequences with fat suppression, performed between 2011 and 2015 were included. FLIS was assigned on the basis of the sum of three hepatobiliary phase features, each scored on an ordinal 0-2 scale: hepatic enhancement, biliary excretion, and the signal intensity in the portal vein. Patients were stratified into the following three groups according to fibrosis stage and a presence or history of hepatic decompensation: nonadvanced CLD, compensated advanced CLD (CACLD), and decompensated advanced CLD (DACLD). The predictive value of FLIS for first and/or further hepatic decompensation and for transplant-free survival was investigated by using Kaplan-Meier analysis, log-rank tests, and Cox regression analysis. Results This study evaluated 265 patients (53 years ± 14 [standard deviation]; 164 men). Intraobserver (κ = 0.98; 95% confidence interval: 0.97, 0.99) and interobserver (κ = 0.93; 95% confidence interval: 0.90, 0.95) agreement for FLIS were excellent. In patients with CACLD, the FLIS was independently predictive of a first hepatic decompensation (adjusted hazard ratio, 3.7; 95% confidence interval: 1.1, 12.6; P = .04), but not for further hepatic decompensations in patients with DACLD (adjusted hazard ratio, 1.4; 95% confidence interval: 0.9, 1.9; P = .17). The FLIS was an independent risk factor for mortality in both patients with CACLD (adjusted hazard ratio, 7.4; 95% confidence interval: 2.7, 20.2; P < .001) and those with DACLD (adjusted hazard ratio, 3.8; 95% confidence interval: 1.7, 9.5; P = .004). Conclusion The functional liver imaging score derived from gadoxetic acid-enhanced MRI identified patients with advanced chronic liver disease who are at increased risk for a first hepatic decompensation and for mortality. © RSNA, 2019 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Bastati N, Beer L, Mandorfer M, et al. Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease? Radiology. 2019. PMID: 31743083. doi:10.1148/radiol.2019190734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。